Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec;11(12):701-11.
doi: 10.1038/nrendo.2015.173. Epub 2015 Oct 13.

Impaired insulin action in the human brain: causes and metabolic consequences

Affiliations
Review

Impaired insulin action in the human brain: causes and metabolic consequences

Martin Heni et al. Nat Rev Endocrinol. 2015 Dec.

Abstract

Over the past few years, evidence has accumulated that the human brain is an insulin-sensitive organ. Insulin regulates activity in a limited number of specific brain areas that are important for memory, reward, eating behaviour and the regulation of whole-body metabolism. Accordingly, insulin in the brain modulates cognition, food intake and body weight as well as whole-body glucose, energy and lipid metabolism. However, brain imaging studies have revealed that not everybody responds equally to insulin and that a substantial number of people are brain insulin resistant. In this Review, we provide an overview of the effects of insulin in the brain in humans and the relevance of the effects for physiology. We present emerging evidence for insulin resistance of the human brain. Factors associated with brain insulin resistance such as obesity and increasing age, as well as possible pathogenic factors such as visceral fat, saturated fatty acids, alterations at the blood-brain barrier and certain genetic polymorphisms, are reviewed. In particular, the metabolic consequences of brain insulin resistance are discussed and possible future approaches to overcome brain insulin resistance and thereby prevent or treat obesity and type 2 diabetes mellitus are outlined.

PubMed Disclaimer

References

    1. Cell Metab. 2007 Jun;5(6):438-49 - PubMed
    1. Psychoneuroendocrinology. 2008 Nov;33(10):1394-400 - PubMed
    1. Diabetes. 2011 Jan;60(1):114-8 - PubMed
    1. Rev Endocr Metab Disord. 2014 Mar;15(1):67-77 - PubMed
    1. Acta Diabetol. 2014 Aug;51(4):679-81 - PubMed

Publication types